To include your compound in the COVID-19 Resource Center, submit it here.

Homologous thinking

While the success of the merger of Versicor Inc. and Biosearch Italia S.p.A. will play out over time, based on what's known today it looks like a template for small biotech M&A. The deal makes sense from the conventional angles - a shared disease focus and increased shots on goal. But unlike many biotech deals, the merger is not being done out of weakness, and it will create operating economies from more than the elimination of redundancies.

Far too many life science M&A transactions are done out of weakness, in which one or both of the companies lack either cash or pipeline depth or both, and claims

Read the full 1068 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE